Orbifloxacin-resistant Mtb H37Ra Genome sequencing and comparsion with wild type

To figure out the anti-M.tb mechanism of orbifloxacin, we obtained an orbifloxacin-resistant M.tb strain and revealed the drug target gene by whole-genome sequencing. A critical point mutation (GyraseD94G) of gyrase gene was identified responsible for orbifloxacin resistance. We demonstrated that the point mutation GyraseD94G can reduce the drug-protein interaction based on the structure docking of Orbifloxacin and Gyrase. Together, we identified Orbifloxacin as a potential anti-M.tb drug which can be used as a therapeutic regimen in combination or in a single form for TB treatment.